CNS Pharmaceuticals's total assets for Q1 2025 were $13.75M, an increase of 58.02% from the previous quarter. CNSP total liabilities were $2.78M for the fiscal quarter, a 10.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.